Showing results (151-160 of 302) with videos related to
Sort By:
Pageof 31
Blood|February 3, 2021
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sairah Ahmed, Fateeha Furqan, et al.British Journal of Haematology|July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky diseaseFelipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.Journal for Immunotherapy of Cancer|December 6, 2018
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceMichael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, et al.Breast Cancer Research : BCR|June 6, 2023
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatmentShuying Liu, Shelly M Xie, Wenbin Liu, et al.Transplantation and Cellular Therapy|July 15, 2021
Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic MalignanciesXin Shelley Wang, Samer A Srour, Meagan Whisenant, et al.Frontiers in Immunology|June 20, 2022
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint BlockadeShubhra Singh, Jason Roszik, Neeraj Saini, et al.Journal for Immunotherapy of Cancer|November 25, 2023
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomasFuliang Chu, Jingjing Cao, Jingwei Liu, et al.Blood Advances|July 15, 2021
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicityUri Greenbaum, Paolo Strati, Rima M Saliba, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2013
Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironmentSeema Rawal, Fuliang Chu, Min Zhang, et al.British Journal of Haematology|April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomasFelipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.Pageof 31